Language:

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Nature reviews. Clinical oncology, 2021-04, Vol.18 (4), p.215-229 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-020-00460-2 ;PMID: 33473220

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Author: Blass, Eryn ; Ott, Patrick A
Subjects: Analysis ; Antigens, Neoplasm - immunology ; Bioinformatics ; Cancer ; Cancer vaccines ; Cancer Vaccines - therapeutic use ; Care and treatment ; Chimeric antigen receptors ; Combined Modality Therapy - methods ; Combined Modality Therapy - trends ; Development and progression ; Health aspects ; History, 21st Century ; Humans ; Immune checkpoint ; Immunogenicity ; Immunologic Factors - therapeutic use ; Immunotherapy ; Immunotherapy - methods ; Immunotherapy - trends ; Lymphocytes ; Lymphocytes T ; Medical research ; Medicine, Experimental ; Melanoma ; Methods ; Neoplasms - immunology ; Neoplasms - therapy ; Patient outcomes ; Patients ; Precision medicine ; Precision Medicine - methods ; Precision Medicine - trends ; Review ; T cells ; T-Lymphocytes - immunology ; T-Lymphocytes - physiology ; T-Lymphocytes - transplantation ; Targeted cancer therapy ; Tumor antigens ; Tumors ; Vaccination ; Vaccines
Is Part Of: Nature reviews. Clinical oncology, 2021-04, Vol.18 (4), p.215-229
Description: Within the past decade, the field of immunotherapy has revolutionized the treatment of many cancers with the development and regulatory approval of various immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies in diverse indications. Another promising approach to cancer immunotherapy involves the use of personalized vaccines designed to trigger de novo T cell responses against neoantigens, which are highly specific to tumours of individual patients, in order to amplify and broaden the endogenous repertoire of tumour-specific T cells. Results from initial clinical studies of personalized neoantigen-based vaccines, enabled by the availability of rapid and cost-effective sequencing and bioinformatics technologies, have demonstrated robust tumour-specific immunogenicity and preliminary evidence of antitumour activity in patients with melanoma and other cancers. Herein, we provide an overview of the complex process that is necessary to generate a personalized neoantigen vaccine, review the types of vaccine-induced T cells that are found within tumours and outline strategies to enhance the T cell responses. In addition, we discuss the current status of clinical studies testing personalized neoantigen vaccines in patients with cancer and considerations for future clinical investigation of this novel, individualized approach to immunotherapy.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 1759-4774
EISSN: 1759-4782
DOI: 10.1038/s41571-020-00460-2
PMID: 33473220
Source: AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-020-00460-2 ;PMID: 33473220

Searching Remote Databases, Please Wait